MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Pfizer Total Current Liabilities 2011-2026 | PFE
Annual Total Current Liabilities Pfizer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 B | 43 B | 47.8 B | 42.1 B | 42.7 B | 25.9 B | 37.3 B | 31.9 B | 30.4 B | 31.1 B | 29.4 B | 21.6 B | 23.4 B | 28.6 B | 28.1 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 47.8 B | 21.6 B | 33.4 B |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | USA |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.47 B | $ 323.46 | -2.98 % | $ 42.4 B | USA |
 |
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
Cabaletta Bio
CABA
|
50.2 M | $ 3.55 | 4.26 % | $ 357 M | USA |
 |
Aligos Therapeutics
ALGS
|
21.2 M | $ 8.1 | 9.16 % | $ 80.1 M | USA |
 |
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 21.91 | 1.04 % | $ 1.02 B | USA |
 |
CymaBay Therapeutics
CBAY
|
36.8 M | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.07 | -3.15 % | $ 5.05 M | Israel |
 |
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | USA |
 |
Galectin Therapeutics
GALT
|
8.03 M | $ 2.3 | -10.35 % | $ 147 M | USA |
 |
ContraFect Corporation
CFRX
|
20.8 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
163 M | $ 1.39 | -10.32 % | $ 357 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.21 | -0.71 % | $ 450 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
130 M | $ 23.86 | -2.93 % | $ 3.04 B | USA |
 |
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.54 | 3.02 % | $ 410 M |  Britain |
 |
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Incyte Corporation
INCY
|
1.52 B | $ 95.06 | -2.11 % | $ 18.6 B | USA |
 |
Caladrius Biosciences
CLBS
|
5.61 M | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
6.81 M | - | - | $ 25.3 M | USA |